Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which ...

Pharma major Bristol Myers Squibb (NYSE: BMY) and US biotech Cabaletta Bio are set to present promising Phase I data on ...

Adaptimmune’s Phase II trial of lete-cel showed a 42% response rate in synovial sarcoma and MRCLS, with strong median ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...